A prospective clinical study on the efficacy and safety of specific uric acid adsorption hemoperfusion in removing serum uric acid from patients with refractory gout
10.13303/j.cjbt.issn.1004-549x.2025.12.008
- VernacularTitle:特异性尿酸吸附血液灌流器去除难治性痛风患者血尿酸的有效性及安全性评价
- Author:
Ying LI
1
;
Yuanming YANG
1
;
Zhongcui JING
1
;
Jiao LIU
1
;
Dandan JIANG
2
;
Shanshan YU
1
;
Haiyan WANG
1
Author Information
1. Department of Blood Transfusion, the Affiliated Hospital of Qingdao University, Qingdao 266003, China
2. Department of Blood Transfusion, Huangdao District People's Hospital, Qingdao 266400, China
- Publication Type:Journal Article
- Keywords:
plasma perfusion;
refractory gout (RG);
efficacy;
safety
- From:
Chinese Journal of Blood Transfusion
2025;38(12):1702-1706
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of the single-use hemoperfusion device (UA230) in treating refractory gout (RG) via plasma perfusion. Methods: Thirty-four RG patients aged 18-65 years were recruited and randomly divided into a control group (febuxostat therapy, n=17) and an experimental group (plasma perfusion combined with febuxostat therapy, n=17). Differences in serum uric acid (SUA) levels and urate-lowering rates between the two groups were analyzed using t-tests. Between-group differences in incidence of adverse reactions were analyzed using chi-square tests. Results: At 7 and 14 days post-treatment, SUA levels in the experimental group were significantly lower than those in the control group, with a higher urate-lowering rate (all P<0.05). However, no statistically significant differences in SUA levels or urate-lowering rate were observed at 28 days post-treatment (all P>0.05). The incidence of adverse reactions showed no significant difference between the two groups (χ
=0.15, P>0.05). Conclusion: The single-use hemoperfusion device (UA230), combined with plasma perfusion technology, is a safe and effective treatment for RG. It may serve as a novel therapeutic approach for RG patients in clinical practice.
